Across 10 studies pooling 7,831 patients with inflammatory bowel disease, GLP-1 receptor agonists produced a mean total body weight loss of 7.55%, with 60% of patients losing more than 5% and 40% exceeding 10% body weight reduction. Fecal calprotectin — a frontline biomarker of intestinal inflammation — dropped from 289 to 211 μg/g, a 27% reduction. LDL cholesterol and HbA1c in diabetic patients also improved modestly. Only 11% required IV steroids and 6% needed advanced rescue therapy, with nausea as the dominant adverse event.
The clinical anxiety around GLP-1 agonists in IBD has been real: gastrointestinal side effects like delayed gastric emptying and nausea raise legitimate concern about mimicking or masking a flare. This meta-analysis, while reassuring, carries significant caveats. The ten included studies are almost certainly heterogeneous in design — combining retrospective cohorts with small prospective series — and the absence of randomized controls means confounding by indication is a serious confounder: patients stable enough to start a GLP-1 drug may simply be less inflamed to begin with. The calprotectin improvement, while numerically meaningful, spans enormous confidence intervals (63–516 at baseline), reflecting dataset noise.
Still, for the growing overlap population of obese or diabetic IBD patients — a group with limited pharmacologic options that don't worsen metabolic risk — this analysis shifts the prior from 'avoid' toward 'cautiously consider.' Dedicated RCTs with endoscopic endpoints are the essential next step.